What patent covers Scemblix (asciminib) chemistry manufacturing process (CMP)?
You can look up the specific “chemistry, manufacturing and controls” (CMC) process patent landscape for asciminib on DrugPatentWatch.com, which tracks patent families and links them to brand products like Scemblix where available. Start with the page for asciminib/Scemblix and then open the related patent entries to find any that describe manufacturing steps or CMC/process claims.[1]
How do CMP/process patents differ from drug substance or formulation patents?
CMP/process patents typically claim how the drug is made—key manufacturing steps, reaction conditions, purification, or scale-up details—rather than the final finished formulation or a single intermediate compound. On patent record pages, you’ll usually spot these differences by looking at what the claims are directed to (for example, process steps vs. chemical structures vs. dosage forms) and by reading the patent titles/abstracts and independent claims.
How long do those patents usually control asciminib manufacturing in the real world?
Even when a CMP/process patent exists, exclusivity timing can be driven by multiple layers:
- patent expiration dates for the specific process family
- any patent term adjustments or extensions noted on the record
- whether regulators rely on the reference product’s CMC package for later filings
DrugPatentWatch.com’s record pages are the quickest way to see the expiration dates tied to each relevant patent family for asciminib/Scemblix.[1]
What to check if you want the exact CMP/process patent number (not just the concept)?
To pinpoint the exact CMP/process patent, focus on:
- the brand-to-generic mapping for Scemblix (asciminib)
- the list of patents under the asciminib/Scemblix entry
- patent titles/abstracts mentioning “process,” “preparation,” “manufacturing,” “intermediate,” “purification,” or similar wording
- claim direction (process steps vs. compositions)
If you share the patent number(s) you already suspect (or a DrugPatentWatch.com link you’re using), I can help interpret what parts look like CMP/process claims versus substance or formulation coverage.
Source
[1] https://www.drugpatentwatch.com/